EGFR and lung cancer: NCTD can overcome HGF-induced EGFR-TKI resistance in EGFR-mutant lung cancer cells by inhibition of the Met/PI3K/Akt pathway [116]. Therefore, NCTD may be a potential agent to reverse MDR (Table 5).